The successful use of 131I as a systemic treatment of a patient with metastatic thyroid cancer
was first reported in 1948 (1). This agent has subsequently become firmly established as …

Thyroid disease management has changed little over the last 60 years and recent work
suggests that the older approach remains the most effective. Treatment of benign …

Recombinant human thyroid-stimulating hormone (rhTSH) was approved for diagnostic
testing by the US Food and Drug Administration in November 1998. It has subsequently …

TO THE EDITOR: Deandreis et al.(1) compared the overall survival (OS) of 2 patient groups
with metastatic differentiated thyroid cancer (mDTC). One group of patients underwent …

Radiotheragnostics represents the systematic integration of diagnostic imaging and
therapeutics using radionuclides targeting specific characteristics of tumor biology …

In the adult population, the differentiated thyroid cancer (DTC) is the most frequent
endocrine neoplasm [1]. According to the American Thyroid Association (ATA) guidelines, in …

Radiotherapy with 131I is the most effective treatment of iodine-avid metastases of
differentiated thyroid cancer. Early diagnosis of metastases and repeated treatment with …

The term theranostics is the combination of a diagnostic tool that helps to define the right
therapeutic tool for specific disease. It signifies the “we know which sites require treatment …

In Nuclear Medicine, radioactive isotopes of iodine have been used in clinical routine for the
diagnosis and treatment of thyroid diseases, especially thyroid cancer for more than 70 …

In the past decade, the management of differentiated thyroid cancer (DTC) underwent a
paradigm shift toward the use of risk stratification with the goal of maximizing the benefit and …